Medpace Holdings, Inc. $MEDP Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 128,599 shares of the company’s stock after selling 30,253 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.46% of Medpace worth $66,120,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Quent Capital LLC acquired a new position in Medpace during the third quarter worth $25,000. Optiver Holding B.V. purchased a new stake in Medpace in the 3rd quarter valued at $27,000. Root Financial Partners LLC acquired a new stake in shares of Medpace in the 3rd quarter worth $38,000. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Finally, Ameriflex Group Inc. raised its holdings in shares of Medpace by 100.0% during the 3rd quarter. Ameriflex Group Inc. now owns 100 shares of the company’s stock worth $51,000 after acquiring an additional 50 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP opened at $477.72 on Thursday. The company’s 50-day simple moving average is $528.39 and its 200-day simple moving average is $539.24. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The stock has a market capitalization of $13.56 billion, a PE ratio of 31.22, a P/E/G ratio of 2.24 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same quarter in the previous year, the business posted $3.67 earnings per share. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on MEDP. Leerink Partners dropped their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a report on Tuesday, February 10th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and dropped their price target for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Finally, Royal Bank Of Canada initiated coverage on shares of Medpace in a report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.